Innovent Biologics, Inc. (HKG:1801)

Innovent Biologics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	17,380	17,345	7,508	10,052	9,163	8,377
Short-Term Investments	2,623	886.74	375.56	867.53	-	-
Trading Asset Securities	-	-	-	50	3.21	638.21
Cash & Short-Term Investments	20,003	18,231	7,884	10,970	9,166	9,015
Cash Growth	109.67%	131.25%	-28.13%	19.68%	1.67%	11.01%
Accounts Receivable	1,903	1,714	1,184	1,006	575.27	968.41
Receivables	1,903	1,714	1,184	1,006	575.27	975.91
Inventory	1,877	1,302	822.17	968.09	1,429	1,347
Other Current Assets	1,223	766.31	382.52	484.38	336.52	212.4
Total Current Assets	25,006	22,013	10,273	13,428	11,507	11,551
Property, Plant & Equipment	5,329	5,441	5,647	4,656	3,826	3,090
Long-Term Investments	8,866	7,860	3,901	794.09	630.2	417.26
Other Intangible Assets	1,468	1,534	1,283	27.79	30.05	19.75
Long-Term Deferred Charges	39.43	99.82	-	1,242	1,168	752.45
Other Long-Term Assets	435.98	399.11	499.02	478.64	427.63	412.07
Total Assets	41,617	37,348	21,603	20,627	17,589	16,244

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	931.37	494.59	357.68	372.55	325.62	195.05
Accrued Expenses	-	4,167	2,739	1,962	1,517	1,678
Current Portion of Long-Term Debt	528.18	789.17	405.1	1,195	888	365
Current Portion of Leases	11.48	11.03	8.83	25.18	26.39	22.27
Current Income Taxes Payable	574	196.15	75.84	194.05	3.3	60.59
Current Unearned Revenue	2,053	2,312	256.41	416.17	434.91	355.51
Other Current Liabilities	5,227	416.87	525.53	312.16	303.71	374.05
Total Current Liabilities	9,325	8,387	4,369	4,477	3,499	3,050
Long-Term Debt	1,763	1,990	2,412	2,327	2,215	2,023
Long-Term Leases	20.59	25.98	4.76	73.42	98.68	86.39
Long-Term Unearned Revenue	9,102	6,946	1,215	960.05	883.28	753.27
Other Long-Term Liabilities	660.61	643.01	483.82	262.71	162.31	0.34
Total Liabilities	20,871	17,992	8,485	8,100	6,859	5,913

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.12	0.12	0.11	0.11	0.11	0.1
Additional Paid-In Capital	-	32,899	27,723	27,324	24,706	22,494
Retained Earnings	-	-15,093	-15,906	-15,768	-14,740	-12,560
Comprehensive Income & Other	20,746	1,550	1,301	970.54	763.86	397.02
Total Common Equity	20,746	19,356	13,118	12,528	10,730	10,330
Shareholders' Equity	20,746	19,356	13,118	12,528	10,730	10,330
Total Liabilities & Equity	41,617	37,348	21,603	20,627	17,589	16,244

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	2,323	2,816	2,831	3,621	3,229	2,497
Net Cash (Debt)	17,680	15,416	5,053	7,349	5,938	6,518
Net Cash Growth	186.97%	205.10%	-31.25%	23.77%	-8.91%	-5.73%
Net Cash Per Share	9.85	8.85	3.10	4.71	3.98	4.48
Filing Date Shares Outstanding	1,726	1,735	1,638	1,622	1,534	1,462
Total Common Shares Outstanding	1,726	1,735	1,638	1,622	1,534	1,462
Working Capital	15,681	13,627	5,904	8,951	8,008	8,501
Book Value Per Share	12.02	11.16	8.01	7.72	6.99	7.07
Tangible Book Value	19,277	17,822	11,835	12,500	10,700	10,311
Tangible Book Value Per Share	11.17	10.27	7.22	7.71	6.97	7.05
Buildings	-	1,783	1,702	402.67	402.46	389.73
Machinery	-	4,029	3,133	4,795	2,523	1,420
Construction In Progress	-	435.33	1,339	6.18	1,139	1,293
Leasehold Improvements	-	571.24	426.63	121.82	107.66	106.85

Data Source: S&P Global Market Intelligence Last updated: Aug 25, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 10, 2026

Data Sources Report a data error